Solid Biosciences (NASDAQ:SLDB) COO Sells $25,202.52 in Stock

Solid Biosciences Inc. (NASDAQ:SLDB) COO David Howton sold 4,932 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $5.11, for a total value of $25,202.52. Following the sale, the chief operating officer owned 32,908 shares in the company, valued at $168,159.88. The trade was a 13.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Solid Biosciences Price Performance

NASDAQ:SLDB opened at $5.77 on Friday. The firm has a market capitalization of $449.54 million, a P/E ratio of -2.32 and a beta of 2.97. The business has a 50 day simple moving average of $5.33 and a 200 day simple moving average of $5.30. Solid Biosciences Inc. has a 12-month low of $2.41 and a 12-month high of $7.37.

Solid Biosciences (NASDAQ:SLDB) last issued its earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Research analysts anticipate that Solid Biosciences Inc. will post -2.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on SLDB shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Solid Biosciences in a research report on Wednesday, October 8th. Citigroup dropped their price target on shares of Solid Biosciences from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Wedbush reduced their price objective on Solid Biosciences from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, August 13th. Chardan Capital restated a “buy” rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. cut their target price on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.82.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SLDB. Legal & General Group Plc raised its holdings in Solid Biosciences by 208.6% during the second quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after purchasing an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in shares of Solid Biosciences by 205.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock worth $33,000 after buying an additional 4,534 shares in the last quarter. Ground Swell Capital LLC bought a new stake in shares of Solid Biosciences in the 1st quarter worth $42,000. Pallas Capital Advisors LLC acquired a new stake in shares of Solid Biosciences in the second quarter valued at $54,000. Finally, Creative Planning bought a new position in Solid Biosciences during the second quarter valued at about $57,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.